163 related articles for article (PubMed ID: 22227917)
1. Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits.
Sekhar MC; Reddy PJ
Mol Cell Biochem; 2012 May; 364(1-2):159-64. PubMed ID: 22227917
[TBL] [Abstract][Full Text] [Related]
2. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Kalliokoski A; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):488-96. PubMed ID: 19238654
[TBL] [Abstract][Full Text] [Related]
3. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
4. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
5. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
Li C; Choi DH; Choi JS
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
[TBL] [Abstract][Full Text] [Related]
6. Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function.
Goud T; Maddi S; Nayakanti D; Thatipamula RP
Drug Metab Pers Ther; 2016 Jun; 31(2):123-30. PubMed ID: 27166727
[TBL] [Abstract][Full Text] [Related]
7. The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.
Badolo L; Bundgaard C; Garmer M; Jensen B
Eur J Pharm Sci; 2013 Jul; 49(4):767-72. PubMed ID: 23648783
[TBL] [Abstract][Full Text] [Related]
8. Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Dong J; Yu X; Wang L; Sun YB; Chen XJ; Wang GJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1247-52. PubMed ID: 18817631
[TBL] [Abstract][Full Text] [Related]
9. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Kanda M; Satoh K; Ichihara K
Biol Pharm Bull; 2003 Dec; 26(12):1681-4. PubMed ID: 14646170
[TBL] [Abstract][Full Text] [Related]
10. Effects of repaglinide on oxidative stress in tissues of diabetic rabbits.
Gumieniczek A
Diabetes Res Clin Pract; 2005 May; 68(2):89-95. PubMed ID: 15860235
[TBL] [Abstract][Full Text] [Related]
11. Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats.
Neerati P; Gade J
Eur J Pharm Sci; 2011 Feb; 42(3):285-9. PubMed ID: 21182938
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
13. Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats.
Malekinejad H; Rokhsartalab-Azar S; Hassani-Dizaj S; Alizadeh-Fanalou S; Rezabakhsh A; Amniattalab A
Eur J Drug Metab Pharmacokinet; 2014 Dec; 39(4):311-20. PubMed ID: 24346850
[TBL] [Abstract][Full Text] [Related]
14. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
15. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Niemi M; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Jul; 70(1):58-65. PubMed ID: 11452245
[TBL] [Abstract][Full Text] [Related]
16. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Kokudai M; Inui N; Takeuchi K; Sakaeda T; Kagawa Y; Watanabe H
J Clin Pharmacol; 2009 May; 49(5):568-73. PubMed ID: 19398603
[TBL] [Abstract][Full Text] [Related]
17. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
18. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Jain S; Saraf S
J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
